Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDRH Details Path Forward For National Post-Market Surveillance System

This article was originally published in The Gray Sheet

Executive Summary

The device center released an updated plan for post-market surveillance reforms, featuring a planning board that will establish a governing structure for the new system, as well as implementation dates for various post-market projects.

You may also be interested in...



Task Force Advocates Making Registries Better Than Sum Of Their Parts

The FDA-endorsed Medical Device Registry Task Force maps out a path toward "coordinated registry networks," starting with pilot projects and 11 prioritized device categories.

Planning Board Urges FDA To Launch Postmarket Incubator Project

FDA and its collaborators should launch an incubator project with fact-finding activities and pilot programs to help launch a national postmarket surveillance system that builds on Unique Device Identifiers (UDIs), registries, and innovative data capture and analysis strategies, a multi-stakeholder planning board recommends.

Planning Board Proposes Postmarket Device Surveillance Timeline

A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.

Related Content

Topics

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel